We are testing the safety and effects of the experimental drug CCS1477 in patients with advanced blood and bone marrow cancers. This study aims to see how well it works alone and in combination with other treatments.
Health conditions and diseases that the clinical trial is designed to study and treat.
Acute Myeloid Leukaemia (AML) is a type of cancer that starts in the blood-forming cells of the bone marrow and leads to the rapid growth of abnormal white blood cells, which can crowd out normal cells and affect blood function.
Myelodysplastic Syndrome (MDS) is a group of disorders caused by poorly formed or dysfunctional blood cells, leading to ineffective blood cell production and symptoms like fatigue and increased risk of infections.
Multiple Myeloma (MM) is a cancer of plasma cells, a type of white blood cell that produces antibodies. It leads to the production of abnormal proteins that can cause damage to bones and organs.
Non-Hodgkin Lymphoma (NHL) is a type of cancer that originates in the lymphatic system, leading to the growth of abnormal lymphocytes. It can cause swollen lymph nodes and other systemic symptoms.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.